Notes
5 Undervalued U.S. Stocks for August 2026: CVS, BBY, UPS, GDDY, NKE
2026-08-27
1. Overview
- Data as of: 2026-08-27
- Stocks reviewed: 10
- Market backdrop: SPY gained roughly 2.7% over the last three months while aggregate Q2 2026 U.S. earnings growth remained strong. The screen therefore required more than a falling share price: relative weakness had to coincide with improving operations, cash flow or guidance.
- Scoring: Fundamental improvement 30%, valuation 25%, balance sheet 15%, catalysts 15%, price dislocation 10%, risk 5%. Scores were calculated once and the Top 5 was then locked.
This is investment research for idea generation, not investment advice.
2. Candidate Comparison
| Rank | Ticker | Company | Sector | 3M Return | Latest Revenue Growth | OPM Change | FCF/Cash Flow | Guidance | Valuation | Key Risk / Catalyst | Score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CVS | CVS Health | Healthcare | +1.7%, about -1.0%p vs SPY | Q2 2026 +7.3% YoY | about +2.0%p GAAP | 1H26 CFO $10.6B vs $6.5B | FY26 EPS and CFO raised | Discounted vs broad market | Medical cost / cash-flow recovery | 87 |
| 2 | BBY | Best Buy | Consumer Discretionary | modest relative performance | Q2 FY27 +3.6% YoY | +1.6%p | 1H CFO $1.30B vs $0.78B | Comp and EPS raised | Mid/low-teens earnings multiple | Consumer demand / AI devices, ads | 84 |
| 3 | UPS | United Parcel Service | Industrials | market-lagging range | Q2 revenue $22.8B, YoY growth positive | Adjusted OPM 9.2%, improved | 1H26 CFO $3.1B | Revenue, operating profit and EPS raised | Forward P/E ~13.6x | Volume/labor / restructuring | 82 |
| 4 | GDDY | GoDaddy | Technology Services | +7.4%, but far below 2025 peak | Growth remained positive | Margin trend improving | Strong recurring FCF | Stable/improving outlook | Discount to prior EV/FCF range | SMB demand / buybacks, mix | 80 |
| 5 | NKE | Nike | Consumer Discretionary | -15.8% | Q4 FY26 -1%; wholesale +4% | gross margin +8.9%p, tariff benefit large | Positive cash generation | Turnaround still early | P/E ~19x | Direct/China / product reset | 78 |
| 6 | EL | Estée Lauder | Consumer Staples | +16.6% | Q4 FY26 +6% | FY26 margin expanded | FY27 CFO guide $1.3-$1.4B | FY27 margin guide raised | Forward P/E ~32x | China / restructuring | 76 |
| 7 | PYPL | PayPal | Fintech | lagged S&P over 1 year | TTM growth positive | Stable/improving | Healthy FCF | Efficiency program intact | P/E ~11.8x; EV/EBITDA ~7.6x | Competition / buybacks | 75 |
| 8 | EBAY | eBay | Consumer Internet | ~14% below May high | Q2 revenue $2.2B | Not confirmed | Not confirmed | Not confirmed | Mature-platform discount | GMV / capital returns | 73 |
| 9 | AMAT | Applied Materials | Semiconductor Equipment | +5.9%; 1M about -8% | Q3 FY26 +25% | +3.1%p | Q3 FCF $2.33B, +14% | Strong 2026/2027 demand view | P/E ~42x, not cheap | Cycle/valuation / AI capex | 70 |
| 10 | FDX | FedEx | Industrials | ~4% below 52-week high | Q4 FY26 +12.6% | -1.9%p GAAP | Not confirmed | Growth outlook positive | Moderate | Margin / Freight separation | 68 |
3. Final Top 5
CVS — CVS Health — 8.7/10
Thesis: Revenue, operating profit and operating cash flow all improved while management raised FY26 EPS and CFO guidance. The market is still focused on medical-cost volatility, but cash generation and deleveraging capacity are recovering faster than the headline narrative suggests.
What the market may be missing: The diversified insurance, pharmacy and services model is producing substantially more cash even before a full normalization of medical-cost trends.
Catalysts: Further guidance raises, medical-cost stabilization, debt reduction.
Risks: Medical-cost reacceleration, regulation, high absolute debt.
Kill conditions: FY26 CFO guidance is cut again or Health Care Benefits profitability deteriorates materially.
Metrics to watch: medical benefit ratio, adjusted operating income, cash flow from operations.
BBY — Best Buy — 8.4/10
Thesis: Q2 FY27 revenue rose 3.6%, comparable sales rose 4.1%, GAAP operating margin improved 1.6 percentage points and first-half CFO rose to $1.30B. Management raised full-year comparable-sales and EPS guidance.
What the market may be missing: Ads, Marketplace and AI-enabled device categories are becoming more important contributors alongside the PC refresh cycle.
Catalysts: AI PCs and wearables, gaming cycle, advertising growth, cost efficiency.
Risks: Consumer slowdown, tariffs and memory costs, fading PC refresh.
Kill conditions: Comparable sales turn negative again and operating margin structurally falls below 4%.
Metrics to watch: comparable sales, operating margin, CFO.
UPS — United Parcel Service — 8.2/10
Thesis: Q2 adjusted operating profit was $2.1B and adjusted margin reached 9.2%; management raised FY26 revenue, adjusted operating-profit and EPS targets.
What the market may be missing: Network restructuring and customer-mix improvement are offsetting part of the cyclical volume pressure.
Catalysts: Annualized restructuring savings, healthcare logistics growth, network productivity.
Risks: Economic slowdown, large-customer volume shifts, labor inflation.
Kill conditions: Renewed adjusted-margin erosion and withdrawal of FY26 EPS guidance.
Metrics to watch: average daily volume, adjusted operating margin, CFO.
GDDY — GoDaddy — 8.0/10
Thesis: Shares remain well below their prior peak while margins, cash flow and buybacks continue to improve. A richer mix of software, commerce and payments supports higher per-share value than the legacy domain-registration narrative implies.
What the market may be missing: Mix shift and share-count reduction can compound per-share FCF even with only moderate top-line growth.
Catalysts: Margin expansion, FCF growth, buybacks, Airo upsell.
Risks: SMB cyclicality, AI website-builder competition, higher acquisition costs.
Kill conditions: Bookings/ARR deceleration occurs together with declining FCF margins.
Metrics to watch: bookings, normalized EBITDA margin, FCF/share.
NKE — Nike — 7.8/10
Thesis: The stock is down about 16% over three months, creating the largest price dislocation in the final group. Q4 FY26 revenue was still down 1%, but wholesale revenue grew 4% and the product/inventory reset is advancing.
What the market may be missing: Weak Direct revenue is dominating the narrative while wholesale normalization, product resets and inventory cleanup are occurring in parallel.
Catalysts: New-product cycle, North American wholesale acceleration, China stabilization.
Risks: Persistent Direct weakness, China demand, one-time tariff-recovery help to margins.
Kill conditions: Currency-neutral revenue declines worsen for two consecutive quarters and wholesale growth rolls over again.
Metrics to watch: currency-neutral revenue, wholesale growth, gross margin excluding tariff effects.
4. Conclusion
- Highest Conviction: CVS
- Best Risk/Reward: NKE
- Most Conservative: BBY
- Highest Rebound Potential: NKE
- Needs Additional Verification: GDDY, particularly the latest detailed FCF and valuation bridge.
Key Sources
- CVS Q2 2026 IR: https://investors.cvshealth.com/news/news-details/2026/CVS-HEALTH-CORPORATION-REPORTS-STRONG-SECOND-QUARTER-2026-RESULTS-AND-RAISES-FULL-YEAR-2026-GUIDANCE/default.aspx
- Best Buy Q2 FY27 IR: https://investors.bestbuy.com/News--Events/news/news-details/2026/Best-Buy-Reports-Second-Quarter-Results/default.aspx
- UPS Q2 2026 IR: https://investors.ups.com/news-events/press-releases/detail/2164/ups-releases-2q-2026-earnings
- Estée Lauder FY2026 IR: https://investors.elcompanies.com/en/news-and-media/newsroom/press-releases/2026/08-19-2026-110037466
- Nike FY2026 Q4 IR: https://investors.nike.com/investors/news-events-and-reports/investor-news/investor-news-details/2026/NIKE-Inc--Reports-Fiscal-2026-Fourth-Quarter-and-Full-Year-Results/default.aspx
- FedEx FY2026 Q4 IR: https://investor.fedex.com/news-and-events/investor-news/investor-news-details/2026/FedEx-Reports-Strong-Fourth-Quarter-and-Full-Year-Results/default.aspx
- Applied Materials Q3 FY2026 IR: https://ir.appliedmaterials.com/news-releases/news-release-details/applied-materials-announces-third-quarter-2026-results
- GoDaddy financials: https://investors.godaddy.net/investor-relations/financials/default.aspx
Not investment advice. Scores and lists are relative snapshots.